Kwality Pharmaceuticals Limited β Q2FY27 earnings call summary
Filed 16 November 2026 Β· Official transcript
- Capex of INR140-150 Cr planned for FY27; INR500-600 Cr over 3 years for expansions; funded mainly by internal accruals
- EBITDA margin guidance 27-28% at INR720-750 Cr revenue; 29-30% margin possible beyond INR1,000 Cr
- H1 FY27 revenue INR343 Cr; FY27 revenue guidance revised upwards to INR720 Cr+
- Acquisition of 4 acres for Unit 7 manufacturing facility; Unit 7 to commercialize 200 BE products by FY30
- FY28 revenue expected INR950-1000 Cr; FY29 target INR1,000 Cr+ with 25-30% growth
- Hormone and biologics segments to contribute INR100-150 Cr and INR80-100 Cr respectively by FY29
- Q2FY27 consolidated revenue grew 63% y-y to INR181 Cr; EBITDA margin 27.5%; PAT doubled to INR29 Cr
- Multiple analyst queries on bioequivalence pipeline, regulatory approvals, and margin sustainability addressed
Open source transcript Β· View Kwality Pharmaceuticals Limited research
Sign in free to track Kwality Pharmaceuticals Limited and receive future summaries.